COMMENTARY

• Japan Should Hone Emergency Approval Scheme Based on Xocova Example
  November 28, 2022

• Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
  November 22, 2022

• Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
  September 28, 2022

• Delving into Potential Implications of Envisaged Price Revision Overhaul
  September 12, 2022

• Generic Industry Has High Hopes on New Expert Panel; Will Its Recommendations Ease Impact of Annual Re-Pricing?
  September 9, 2022

• Tussle in Japan Diabetes Market Heating Up; BI and Sumitomo Nip and Tuck for No. 1 Slot
  August 29, 2022

• Launch of New Expert Panel Nears, How Can It Make Its Proposal Productive?
  August 25, 2022

• Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt
  August 22, 2022

• Govt Should Examine Challenges with Emergency Approval Scheme Exposed by Shionogi Pill Review
  July 25, 2022

• Japan Set to Build Legal Framework for Health Data Use as Initiative Enshrined in Honebuto 2022
  July 25, 2022

• Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
  June 27, 2022

• New Zero Premium Rule Applied to 6 Drugs Since April Rollout, Is It Incentivizing Cost Disclosure?
  June 2, 2022

• Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
  May 10, 2022

• SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
  April 22, 2022

• Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
  April 19, 2022

• Drug Makers Forced to Make Tough Decisions on AG Strategies: Licensing Profits or Losses on Early G1 Cuts?
  April 8, 2022

• Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll
  March 16, 2022

• Drug Makers in Japan Increasingly Tested for Product Prowess, Rather than Marketing Ability
  February 25, 2022

• Will New Economic Security Bill Contribute to Ensuring Stable Drug Supplies?
  February 16, 2022

• JPMA Chief’s Comments to Endorse Coverage Review Send Ripples through Industry
  February 3, 2022

ページ